Critical Evaluation of Nanoparticle Tracking Analysis (NTA) by NanoSight for the Measurement of Nanoparticles and Protein Aggregates

Overview

Journal Pharm Res

Specialties Pharmacology
Pharmacy

Date 2010 Mar 6

PMID 20204471

Citations 463

Authors

Vasco Filipe

Andrea Hawe

Wim Jiskoot

Affiliations

Soon will be listed here.

Abstract

Purpose: To evaluate the nanoparticle tracking analysis (NTA) technique, compare it with dynamic light scattering (DLS) and test its performance in characterizing drug delivery nanoparticles and protein aggregates.

Methods: Standard polystyrene beads of sizes ranging from 60 to 1,000 nm and physical mixtures thereof were analyzed with NTA and DLS. The influence of different ratios of particle populations was tested. Drug delivery nanoparticles and protein aggregates were analyzed by NTA and DLS. Live monitoring of heat-induced protein aggregation was performed with NTA.

Results: NTA was shown to accurately analyze the size distribution of monodisperse and polydisperse samples. Sample visualization and individual particle tracking are features that enable a thorough size distribution analysis. The presence of small amounts of large (1,000 nm) particles generally does not compromise the accuracy of NTA measurements, and a broad range of population ratios can easily be detected and accurately sized. NTA proved to be suitable to characterize drug delivery nanoparticles and protein aggregates, complementing DLS. Live monitoring of heat-induced protein aggregation provides information about aggregation kinetics and size of submicron aggregates.

Conclusion: NTA is a powerful characterization technique that complements DLS and is particularly valuable for analyzing polydisperse nanosized particles and protein aggregates.

Citing Articles

Optical label-free microscopy characterization of dielectric nanoparticles.

Garcia Rodriguez B, Olsen E, Skarberg F, Volpe G, Hook F, Midtvedt D Nanoscale. 2025; .

PMID: 40079204 PMC: 11904879. DOI: 10.1039/d4nr03860f.

Anti-Inflammatory and Immunomodulatory Properties of Inorganic Fullerene-Like Tungsten Disulfide Nanoparticles in the Culture of Human Peripheral Blood Mononuclear Cells.

Zecevic S, Popovic D, Tomic S, Bekic M, Rakocevic S, Kosanovic M Nanomaterials (Basel). 2025; 15(5).

PMID: 40072125 PMC: 11901739. DOI: 10.3390/nano15050322.

A synthetic model of bioinspired liposomes to study cancer-cell derived extracellular vesicles and their uptake by recipient cells.

Lopez R, Ben El Khyat C, Chen Y, Tsering T, Dickinson K, Bustamante P Sci Rep. 2025; 15(1):8430.

PMID: 40069225 PMC: 11897354. DOI: 10.1038/s41598-025-91873-5.

Development of a cell-penetrating peptide-based nanocomplex for long-term delivery of intact mitochondrial DNA into epithelial cells.

Wilson K, Holjencin C, Lee H, Annamalai B, Ishii M, Gilbert J Mol Ther Nucleic Acids. 2025; 36(1):102449.

PMID: 39991470 PMC: 11847061. DOI: 10.1016/j.omtn.2025.102449.

Scalable production of anti-inflammatory exosomes from three-dimensional cultures of canine adipose-derived mesenchymal stem cells: production, stability, bioactivity, and safety assessment.

Thongsit A, Oontawee S, Siriarchavatana P, Rodprasert W, Somparn P, Na Nan D BMC Vet Res. 2025; 21(1):81.

PMID: 39979916 PMC: 11841348. DOI: 10.1186/s12917-025-04517-1.

References

Hvidt S . Insulin association in neutral solutions studied by light scattering. Biophys Chem. 1991; 39(2):205-13. DOI: 10.1016/0301-4622(91)85023-j. View

Schellekens H . Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov. 2002; 1(6):457-62. DOI: 10.1038/nrd818. View

Mahler H, Muller R, Friess W, Delille A, Matheus S . Induction and analysis of aggregates in a liquid IgG1-antibody formulation. Eur J Pharm Biopharm. 2005; 59(3):407-17. DOI: 10.1016/j.ejpb.2004.12.004. View

Jiskoot W, van Schie R, Carstens M, Schellekens H . Immunological risk of injectable drug delivery systems. Pharm Res. 2009; 26(6):1303-14. DOI: 10.1007/s11095-009-9855-9. View

Cromwell M, Hilario E, Jacobson F . Protein aggregation and bioprocessing. AAPS J. 2006; 8(3):E572-9. PMC: 2761064. DOI: 10.1208/aapsj080366. View

Philo J . A critical review of methods for size characterization of non-particulate protein aggregates. Curr Pharm Biotechnol. 2009; 10(4):359-72. DOI: 10.2174/138920109788488815. View

Brown P, Schuck P . Macromolecular size-and-shape distributions by sedimentation velocity analytical ultracentrifugation. Biophys J. 2006; 90(12):4651-61. PMC: 1471869. DOI: 10.1529/biophysj.106.081372. View

Bee J, Stevenson J, Mehta B, Svitel J, Pollastrini J, Platz R . Response of a concentrated monoclonal antibody formulation to high shear. Biotechnol Bioeng. 2009; 103(5):936-43. PMC: 2724069. DOI: 10.1002/bit.22336. View

Frokjaer S, Otzen D . Protein drug stability: a formulation challenge. Nat Rev Drug Discov. 2005; 4(4):298-306. DOI: 10.1038/nrd1695. View

10.

Carpenter J, Randolph T, Jiskoot W, Crommelin D, Middaugh C, Winter G . Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality. J Pharm Sci. 2008; 98(4):1201-5. PMC: 3928042. DOI: 10.1002/jps.21530. View

11.

Slutter B, Plapied L, Fievez V, Sande M, des Rieux A, Schneider Y . Mechanistic study of the adjuvant effect of biodegradable nanoparticles in mucosal vaccination. J Control Release. 2009; 138(2):113-21. DOI: 10.1016/j.jconrel.2009.05.011. View

12.

Frisken B . Revisiting the method of cumulants for the analysis of dynamic light-scattering data. Appl Opt. 2008; 40(24):4087-91. DOI: 10.1364/ao.40.004087. View

13.

Mahato R, Narang A, Thoma L, Miller D . Emerging trends in oral delivery of peptide and protein drugs. Crit Rev Ther Drug Carrier Syst. 2003; 20(2-3):153-214. DOI: 10.1615/critrevtherdrugcarriersyst.v20.i23.30. View

14.

Mahler H, Friess W, Grauschopf U, Kiese S . Protein aggregation: pathways, induction factors and analysis. J Pharm Sci. 2008; 98(9):2909-34. DOI: 10.1002/jps.21566. View

15.

Bootz A, Vogel V, Schubert D, Kreuter J . Comparison of scanning electron microscopy, dynamic light scattering and analytical ultracentrifugation for the sizing of poly(butyl cyanoacrylate) nanoparticles. Eur J Pharm Biopharm. 2004; 57(2):369-75. DOI: 10.1016/S0939-6411(03)00193-0. View

16.

Fraunhofer W, Winter G, Coester C . Asymmetrical flow field-flow fractionation and multiangle light scattering for analysis of gelatin nanoparticle drug carrier systems. Anal Chem. 2004; 76(7):1909-20. DOI: 10.1021/ac0353031. View

17.

Lipinski C . Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods. 2001; 44(1):235-49. DOI: 10.1016/s1056-8719(00)00107-6. View